AMRX vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMRX's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns about operational efficiency and profitability sustainability. The absence of an Altman Z-Score and a Debt/Equity ratio of 450.96 signal extreme leverage and potential distress risk, severely undermining financial stability. Despite strong revenue growth (11.5% YoY) and impressive earnings surprises (average +26.6% over last 4 quarters), the stock trades at a forward P/E of 10.12 but a trailing P/E of 53.77, suggesting overvaluation relative to current earnings. The lack of dividends, negative Price/Book, and bearish insider activity further erode investor confidence. The stock's 1-month decline of 19.5% reflects deteriorating market sentiment despite a strong 3-year return.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AMRX vs JNJ: Head-to-Head Comparison
This page compares Amneal Pharmaceuticals, Inc. (AMRX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.